Compare Lithium Americas Corp (LAC) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lithium Americas Corp vs Novartis AG — how do they compare? Lithium Americas Corp trades at $2.36 (market cap $850.38M), while Novartis AG trades at $143.75 (market cap $268.57B). The key difference: Novartis AG is far larger — about 315.8× Lithium Americas Corp's market cap, and Novartis AG pays a 3.31% dividend while Lithium Americas Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Lithium Americas Corp for 27 Days and Novartis AG for 82 Days on average.
| LAC | NVS | |
|---|---|---|
Market Cap | $850.38M | $268.57B |
Volume | 8,804,637 | 1,532,573 |
Sector | Basic Materials | Health |
52-Week High | $10.05 | $168.62 |
52-Week Low | $2.36 | $121.80 |
Typical Hold Time | 27 Days | 82 Days |
Enterprise Value | $1.19B | $309.89B |
Dividend Yield | — | 3.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lithium Americas (LAC) trades at $2.35, down 2.49% on the day, with a bearish technical outlook despite recent earnings beats. The company shows negative profitability metrics (ROE -9.56%, ROA -3.99%) and zero revenue in 2025, though construction progress at Thacker Pass provides potential upside. Analyst consensus is mixed with 7 buy and 8 hold ratings, pointing to a $4.00 price target representing 70% upside from current levels.
LAC presents a high-risk, high-reward opportunity as it transitions from development to execution phase. The primary investment thesis hinges on successful Thacker Pass development and lithium price recovery, while key risks include project execution challenges, negative cash flow from operations, and volatile lithium markets. Current valuation at 0.6x book value suggests potential undervaluation if operational milestones are met.
Novartis (NVS) trades at $143.75, up 0.33% on the day, near the consensus price target of $146.00. Recent earnings show mixed quarterly beats and a miss in Q1 2026, with revenue growth to $56.67B in 2025 and a net income margin of 24.67%. Technical indicators signal a bearish trend, while analyst sentiment is mixed with 24% buy ratings. The company recently announced a $7.8B licensing deal with China's Abogen for mRNA therapy, but faces scrutiny over clinical setbacks and M&A strategy.
The outlook for NVS hinges on execution of its pipeline and deal integration amid investor caution. Opportunities include expansion into autoimmune treatments and solid profitability, but risks involve trial failures, regulatory probes, and debt levels rising to 30.26% of assets. Wall Street remains neutral with a slight upside to the price target.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lithium Americas Corp
Lithium Americas is a resource company focused on developing the Thacker Pass project in Nevada, the largest known lithium resource in the US. It aims to become a major supplier for the electric vehicle battery market.
Read more on LAC →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
